Literature DB >> 6315395

Common multigenic activation in different human neoplasias.

N Hanania, D Shaool, J Harel, J Wiels, T Tursz.   

Abstract

It was previously shown that a common multigenic component, designated as tumor-specific DNA (tsDNA), was transcriptionally active in human lymphoid neoplasias and only slightly active, if at all, in normal lymphoid cells, including the Priess cell line immortalized by Epstein-Barr virus. In the Burkitt lymphoma-derived Raji cell line, tsDNA corresponded to 2500-3000 distinct transcription units, arbitrarily defined as encoding mRNA chains of 1000 kds each. In the present study, radioactive Raji cell tsDNA was isolated by a recycling procedure which eliminates transcribed DNA sequences common to both the Raji cell and the Priess cell, and was used as a probe for homologous transcripts. The major part of this probe could be hybridized to RNAs from all the human neoplasias studied: cultured cell lines derived from leukemias, malignant lymphomas or sarcomas, leukemic cells or solid tumors (sarcomas and carcinomas) recovered from patients. In contrast, only a minor portion of Raji cell tsDNA could be hybridized to RNAs from non-malignant cells, normal human lymphoid cells or fibroblasts grown in culture, fetal and chorioplacental tissues. It is concluded that a common multigenic set is activated in a wide variety of, and perhaps in all, human neoplasias.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315395      PMCID: PMC555336          DOI: 10.1002/j.1460-2075.1983.tb01635.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  32 in total

1.  The extensive homology between mRNA sequences of normal and SV40-transformed human fibroblasts.

Authors:  J G Williams; R Hoffman; S Penman
Journal:  Cell       Date:  1977-08       Impact factor: 41.582

2.  Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin.

Authors:  C Shih; B Z Shilo; M P Goldfarb; A Dannenberg; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

3.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.

Authors:  S J Collins; R C Gallo; R E Gallagher
Journal:  Nature       Date:  1977-11-24       Impact factor: 49.962

Review 4.  Retrodifferentiation and the fetal patterns of gene expression in cancer.

Authors:  J Uriel
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

5.  Ribonucleic acid isolated by cesium chloride centrifugation.

Authors:  V Glisin; R Crkvenjakov; C Byus
Journal:  Biochemistry       Date:  1974-06-04       Impact factor: 3.162

6.  Tumor-specific polyadenylated RNA's from 7,12-dimethylbenz(a)anthracene-induced mammary tumors revealed through hybridization with fractionated single-copy DNA.

Authors:  S C Supowit; J M Rosen
Journal:  Cancer Res       Date:  1981-10       Impact factor: 12.701

Review 7.  The origin of human cancers.

Authors:  J Cairns
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

8.  Polypeptide maps of cells infected with murine type C leukemia or sarcoma oncovirus.

Authors:  M Strand; J T August
Journal:  Cell       Date:  1978-02       Impact factor: 41.582

9.  Transforming activity of human tumor DNAs.

Authors:  T G Krontiris; G M Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

10.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.

Authors:  C Shih; L C Padhy; M Murray; R A Weinberg
Journal:  Nature       Date:  1981-03-19       Impact factor: 49.962

View more
  2 in total

Review 1.  An approach to oncological genetics.

Authors:  P Tautu; G Wagner
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

2.  The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors.

Authors:  L M Matrisian; G T Bowden; P Krieg; G Fürstenberger; J P Briand; P Leroy; R Breathnach
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.